AAPG vs REGN: Which Stock is Better?
Side-by-side comparison of Ascentage Pharma Group International and Regeneron Pharmaceuticals Inc in 2026
AAPG
Ascentage Pharma Group International
$26.01
REGN
Regeneron Pharmaceuticals Inc
$733.78
Key Metrics Comparison
| Metric | AAPG | REGN | Winner |
|---|---|---|---|
| Market Cap | $2.53B | $77.77B | REGN |
| P/E Ratio | N/A | 17.58 | REGN |
| EPS (TTM) | $N/A | $41.75 | REGN |
| Revenue Growth | -0.7% | 0.0% | REGN |
| Gross Margin | 90.9% | 45.8% | AAPG |
Analyze AAPG
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is AAPG or REGN a better investment?
Comparing AAPG and REGN: Ascentage Pharma Group International has a market cap of $2.53B while Regeneron Pharmaceuticals Inc has $77.77B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between AAPG and REGN?
AAPG (Ascentage Pharma Group International) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: AAPG or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: AAPG or REGN?
REGN has higher revenue growth at 0.0% vs -0.7% for AAPG.
Which company is more profitable: AAPG or REGN?
Ascentage Pharma Group International (AAPG) has higher gross margins at 90.9% compared to 45.8% for REGN.
Which is the larger company: AAPG or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $77.77B compared to $2.53B for AAPG.
Should I buy AAPG or REGN in 2026?
Both AAPG and REGN have investment merit. AAPG trades at $26.01 while REGN trades at $733.78. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between AAPG and REGN stock?
Key differences: Market Cap ($2.53B vs $77.77B), P/E Ratio (N/A vs 17.6x), Revenue Growth (-0.7% vs 0.0%), Gross Margin (90.9% vs 45.8%).